HomeAbout

TL;DR CNBC


Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs - TL;DR CNBC

Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs

Publishing timestamp: 2024-07-26 11:03:23


Summary

Bristol Myers Squibb reported strong second-quarter earnings and revenue, raised full-year guidance, and plans to cut costs by $1.5 billion by 2025. Revenue growth driven by blockbuster drug Eliquis and other key treatments. Shares rose nearly 8% on the news.


Sentiment: POSITIVE

Tickers: PFEBMY

Keywords: breaking newsbusinessbreaking news: businessbristol-myers squibb cobusiness newsbiotechnologybiotech and pharmaceuticalshealth care industryjoe bidenearningspfizer incpharmaceuticals

Source: https://www.cnbc.com/2024/07/26/bristol-myers-squibb-bmy-earnings-q2-2024.html


Developed by Leo Phan